Navigation Links
Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
Date:6/16/2009

Pitavastatin represents important treatment option for more vulnerable populations

BOSTON, June 16 /PRNewswire/ -- New data presented today showed that pitavastatin is an effective treatment for the management of dyslipidemia in elderly patients, with a similar safety and tolerability profile to low-dose pravastatin. The Phase III data were presented today by Kowa, at the XV International Symposium on Atherosclerosis in Boston.

"This study shows the effectiveness of pitavastatin to lower LDL [low-density lipoprotein] cholesterol in a group of elderly patients with primary hypercholesterolemia or combined dyslipidemia," said Professor Steen Stender, M.D., Ph.D., Gentofte University Hospital, Denmark, and an investigator for the study. "When compared to the usual daily dosage of 40 mg pravastatin, a 4-mg dosage of pitavastatin demonstrated greater LDL-cholesterol lowering with no significant safety difference across all doses, and may represent a more favorable treatment option for such target populations."

The Phase III, active-controlled study was conducted for 12 weeks to compare the safety and efficacy of pitavastatin (1 mg, 2 mg and 4 mg) and pravastatin (10 mg, 20 mg and 40 mg) in patients aged more than or equal to 65 years with primary hypercholesterolemia or combined dyslipidemia. About half of the patients had hypertension, 5 percent had diabetes and about 80 percent were taking concomitant medications. A 60-week, open-label extension to this core study was conducted to assess the long-term safety of pitavastatin at the recommended starting dose of 2 mg once daily, and the need for up-titration to 4 mg once daily in consenting completers from the pitavastatin treatment groups of the core study.

The results of the core study demonstrated that pitavastatin was statistically superior to pravastatin across all three dose comparisons as measured by percent change from baseline in LDL-C (P<.001), and that a higher percentage of patients achieved LDL-C goal with pitavastatin 2 mg and 4 mg than in any other treatment group. All three doses of pitavastatin demonstrated a comparable safety profile to low-dose pravastatin. In addition, results from the extension study showed maintenance of the efficacy and safety of pitavastatin 2 mg and 4 mg through 60 weeks.

"The results of this study show that pitavastatin has a robust efficacy, safety and tolerability profile at the proposed starting dose and offers a low-dose alternative for vulnerable populations, such as the elderly," said Neil Hounslow, vice president of scientific affairs, Kowa Research Europe. "It may be difficult to choose a suitable statin for elderly patients with primary hypercholesterolemia or combined dyslipidemia who are taking other medications, and this study demonstrates that the majority of these patients can achieve and sustain goal with the starting dose of 2 mg of pitavastatin once daily."

About pitavastatin

Pitavastatin (a statin) is a fully synthetic and highly potent inhibitor of HMG-CoA reductase used for primary hypercholesterolemia and combined dyslipidemia. Pitavastatin has a unique cyclopropyl group on the base structure common to the statin class. Since its 2003 launch in Japan, pitavastatin has accumulated millions of patient-years of exposure. Many of these patients have comorbidities and are taking multiple medications. Kowa has filed a New Drug Application for pitavastatin with the U.S. Food and Drug Administration and expects a response from the agency in Q3 of 2009. Once approved, pitavastatin will be available in the United States in three dosage strengths (1, 2 and 4 mg).

About Kowa Company Ltd. and Kowa Pharmaceuticals America, Inc.

Kowa Company, Ltd. is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products. Kowa's pharmaceutical division is focused on cardiovascular therapeutics, with fiscal year 2008 sales of the company's flagship product, LIVALO(R) (pitavastatin) totaling $340 million in Japan.

Kowa Pharmaceuticals America, Inc. is a specialty pharmaceutical company focused primarily in the area of cardiology. The company, started in 2001 as ProEthic Pharmaceuticals, Inc., was acquired by Kowa Company, Ltd. in September of 2008. A privately held company, KPA focuses its efforts on the acquisition, development, licensing and marketing of pharmaceutical products. Its lead product, LIPOFEN(R) (fenofibrate capsules), is indicated as adjunctive therapy to diet to reduce elevated triglycerides and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

For more information about KPA, please visit www.kowapharma.com.


'/>"/>
SOURCE Kowa Company Ltd. and Kowa Pharmaceuticals America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
2. UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
3. Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment
4. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
5. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
6. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
7. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
8. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
9. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
10. Study Shows GSKs Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
11. New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients Blood Sugar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
Breaking Medicine News(10 mins):